Gregory Glenn on next steps for Novavax’s COVID-19 vaccine 

Novavax has proposed that FDA accept final data from a U.K. Phase III study of its COVID-19 vaccine candidate, supplemented by data from a Phase II study conducted in South Africa, as the basis for an emergency use authorization, the company’s president for R&D, Gregory Glenn, told BioCentury.

Novavax Inc. (NASDAQ:NVAX) does not know if FDA will accept the proposal or if it will require additional data from a larger Phase III trial that is under way in the U.S. and Mexico, he said. ...